Johnson & Johnson (JNJ) voluntarily recalled all infant Tylenol in United States, after receiving few complaints from parents who reported difficulty using the Infants' TYLENOL SimpleMeasure dosing system.
J&J's McNeil Consumer Healthcare unit recalled seven lots, about 574,000 bottles of grape-flavored Infants Tylenol from stores nationwide on Friday.TYLENOL is an over-the-counter product indicated as a pain reliever/fever reducer. Children's TYLENOL products are intended for children two years of age and older and remain available.
SimpleMeasure includes a dosing syringe, which a parent or caregiver inserts into a protective cover, or flow restrictor, at the top of the bottle to measure the proper dose. In some cases, the flow restrictor was pushed into the bottle when inserting the syringe. No adverse events associated with this action have been reported to date and the risk of a serious adverse medical event is remote. Consumers can continue to use Infants' TYLENOL provided the flow restrictor at the top of the bottle remains in place. If the flow restrictor is pushed into the bottle, the parent or caregiver should not use the product.
The company said customers can continue to use the infant Tylenol if the bottle's flow restrictor remains intact. If not, they can request a refund by contacting McNeil at 1-888-222-6036 or www.tylenol.com.
Since 2009, the company's McNeil Consumer Healthcare recalled several over-the-counter or OTC, medicines, including Tylenol, Benadryl, Motrin, Zyrtec, Sudafed, Sinutab and Rolaids. The recalls prompted J&J to shut down a factory and have cost it more than $1 billion in lost sales.
JNJ closed Friday's regular trading session at $64.99, up $0.07. In after-hours trading, the shares further rose 0.06% to and ended at $65.03.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.